Moderna – Talk Bio

Actionable Insights Powered by AI

FDA Approves Moderna’s Next-Generation Covid Vaccine With Limited Use for Most Healthy People

4 days ago talkbio0Tagged Approved, COVID19 (disease), Elderly (population group), high-risk, Moderna, next-generation Covid vaccine, Omicron, Omicron JN.1, restrictions, Spikevax, United States Food and Drug Administration, Vaccines, Variant

Moderna; FDA approval; mNexspike; next-generation Covid vaccine; vaccine restrictions; Covid-19; Spikevax; elderly; high-risk medical conditions; Omicron JN.1 variant

Moderna’s Next-Generation COVID Shot Gets FDA Backing With Usage Limitations

6 days ago talkbio0Tagged age restriction, Approved, conditions, COVID19 (disease), Effectiveness, mNEXSPIKE, Moderna, mRNA-1283, next-generation vaccine, respiratory virus season, United States Food and Drug Administration, Vaccines

Moderna; COVID-19 vaccine; FDA approval; mNEXSPIKE; mRNA-1283; next-generation vaccine; respiratory virus season; age restriction; underlying conditions; vaccine efficacy

Trump Administration Cancels Major Federal Funding for Moderna’s Bird Flu Vaccine

1 week ago talkbio0Tagged Administration occupational activities, bird flu vaccine, cancellation, CHARGE Syndrome, H5 avian influenza, HHS, Moderna, mRNA Vaccine, pandemic preparedness, Transplant Registry Unified Management Program

Trump administration; Moderna; bird flu vaccine; HHS; funding cancellation; mRNA vaccine; pandemic preparedness; H5 avian influenza

Uncertainty Surrounds Moderna’s Next-Generation COVID Shot Amid Policy Changes

2 weeks ago talkbio0Tagged COVID19 (disease), flu/COVID-19, Moderna, Policy, Recommendation, Regulatory Setback, United States Food and Drug Administration, vaccine access, Vaccines

Moderna; COVID-19 vaccine; FDA policy; combination flu/COVID-19 shot; vaccine access; mRNA-1083; vaccine recommendations; regulatory setback

Moderna Shares Fall as Company Withdraws Flu/COVID-19 Combination Vaccine Application

2 weeks ago talkbio0Tagged Biologics License Application, Clinical Trials, COVID19 (disease), Effectiveness, Influenza, Moderna, mRNA-1083, Prices, United States Food and Drug Administration, Vaccines, Vaccines, Combined

Moderna; mRNA-1083; combination vaccine; flu; COVID-19; FDA; Biologics License Application; vaccine efficacy; clinical trial; share price

Moderna expands effort to rein in costs in an uncertain environment

1 month ago talkbio0Tagged Environment, Financial cost, Moderna, Uncertainty

Moderna, Financial cost, Uncertainty, Environment

Leadership Changes at Agios and Moderna: Board Resignation and New Marketing Chief

4 months ago talkbio0Tagged Agios, Board Resignation, Changing, Chief, David Schenkein, Drug Industry, Leadership, Mahery, marketing officer, Moderna

David Schenkein, Agios Pharmaceuticals, board resignation, Moderna, Amy Mahery, chief marketing officer, pharmaceutical industry, leadership changes

HHS Awards Moderna $590 Million to Expedite Bird Flu Vaccine Development

5 months ago talkbio0Tagged Aves, CHARGE Syndrome, Moderna, mRNA Vaccine, pandemic preparedness, Vaccines

Moderna, HHS, Bird Flu Vaccine, Avian Influenza, mRNA Vaccine, Pandemic Preparedness

Moderna Slashes 2025 Revenue Forecast, Expands Cost-Cutting Measures Amid Vaccine Sales Decline

5 months ago talkbio0Tagged 2025, competition, cost-cutting measures, COVID19 (disease), decline, Market, Moderna, Vaccination, Vaccines

Moderna, 2025 revenue forecast, cost-cutting measures, vaccine sales decline, COVID-19 vaccine market competition, falling vaccination rates.

Moderna Co-Founder Kenneth Chien’s New Biotech Secures $950M RNA Deal with Etherna

5 months ago talkbio0Tagged Chien, deal, Etherna, Kenneth, Moderna, mRNA therapies, RNA

Kenneth Chien, Moderna, Etherna, RNA deal, biotech, mRNA therapies